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Peroxisome proliferator-activated receptors (PPARs) were discovered over a decade ago, and were classiﬁed as orphan members of
the nuclear receptor superfamily. To date, three PPAR subtypes have been discovered and characterized (PPARα, β/δ, γ). Diﬀerent
PPAR subtypes have been shown to play crucial roles in important diseases and conditions such as obesity, diabetes, atherosclerosis,
cancer, and fertility. Among the most studied roles of PPARs is their involvement in inﬂammatory processes. Numerous studies have
revealed that agonists of PPARα and PPARγ exert anti-inﬂammatory eﬀects both in vitro and in vivo. Using the carrageenan-induced
paw edema model of inﬂammation, a recent study in our laboratories showed that these agonists hinder the initiation phase, but not
the late phase of the inﬂammatory process. Furthermore, in the same experimental model, we recently also observed that activation of
PPARδ exerted an anti-inﬂammatory eﬀect. Despite the fact that exclusive dependence of these eﬀects on PPARs has been questioned,
the bulk of evidence suggests that all three PPAR subtypes, PPARα,δ,γ, play a signiﬁcant role in controlling inﬂammatory responses.
Whether these subtypes act via a common mechanism or are independent of each other remains to be elucidated. However, due to the
intensity of research eﬀorts in this area, it is anticipated that these eﬀorts will result in the development of PPAR ligands as therapeutic
agents for the treatment of inﬂammatory diseases.
INTRODUCTION
A group of nuclear receptors, termed peroxisome
proliferator-activated receptors (PPARs), was identiﬁed
during the last decade [1]. These receptors, which belong
to the steroid hormone receptor superfamily, bind to and
are activated by fatty acids, eicosanoids, and numerous
structurally dissimilar xenobiotics, known collectively as
peroxisome proliferators (see [2]; Figure 1 and Table 1).
Three related PPAR isotypes have been identiﬁed to
date; PPAR α,P P A Rβ/δ,a n dP P A Rγ [3, 4]. Studies have
documented the existence of human forms of PPARα (h
PPARα;[ 5, 6]) and PPARγ (hPPAR γ;[ 7]). The tissue dis-
tribution pattern of hPPAR α mRNA is similar to that of
theratPPARα.I nbothspeciesPP ARαishighlyexpressed
in brown adipose tissue, skeletal muscle, liver, heart, and
kidney, while expressed at low levels in the brain and lung
[6, 8]. The principal site of expression of PPAR γ is the
adipose tissue, but this receptor is also expressed, albeit at
lower levels, in many other tissues and cell types such as
the retina, some parts of the immune system, mammary
and colonic epithelium [9]. PPAR δ subtype is found in
higher amounts than PPAR α and PPAR γ in almost all
tissues examined, except the adipose tissue [10]. PPARδ
is expressed ubiquitously in the rat cerebellum, thalamus
and cerebellar cortex [11], and speciﬁc PPARδ agonists,
and to a much lesser extent those of PPARγ, stimulated
oligodendrocyte diﬀerentiation in vitro [12].
The chromosomal localization of the human and
mouse PPAR genes has been identiﬁed [3]. The human
PPARα (h PPARα) was mapped on chromosome 22 [3].
The hPPAR γ gene is located on chromosome 3 and the
hPPAR δ has been assigned to chromosome 6 [3]. In the
mouse, PPAR γ is located on chromosome 6, while PPAR
α and PPAR δ are found on chromosomes 15 and 17, re-
spectively [3].
DNAbindingpropertiesofPPARs
The DNA binding domain is the most conserved do-
main among all nuclear hormone receptors, and is the
hallmark of this superfamily of receptors. The DBD is
formed by two zinc ﬁnger-like motifs folded in a globu-
lar structure that can recognize a DNA target composed
of 6 nucleotides [3]. In most cases, nuclear hormone re-
ceptors bind as dimers to two copies of such a core motif,
which constitute a functional hormone response element
[3]. The spacing of the two motifs and their relative ori-
entation determine which receptors bind to a given hor-
mone response element [3].
Peroxisome proliferator-activated receptor response
element (PPRE) is deﬁned as a direct repeat of two core
recognition motifs AGGTCA spaced by one nucleotide
[3]. PPAR interacts with the upstream extended core hex-
amer of the PPRE [3]. The fact that some tissues express
more than one PPAR isotype suggests the presence of
PPAR isotype-speciﬁc PPRE recognition [3]. PPREs are2004:3 (2004) PPARs and Inﬂammation 157
Table 1. Relative PPAR subtype-speciﬁcity of selected agonists.
Agonist PPAR subtype
αβ / δ γ
Wy-14,643 +++ −−− +
L-165041 −−− +++ +
Rosiglitazone −−− −−− +++
(+ + +): high activity, (+): weak activity, (−−− ): no activity. Data are
derived from references [4, 10, 12, 13].
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Figure 1. Chemical structures of representative PPAR agonists.
PPARα: Wy-14,643, PPAR β/δ: L-165041, and PPARγ: Rosiglita-
zone.
classiﬁed into three functional groups: strong, intermedi-
ate, and weak elements. The PPAR DNA binding activ-
ity is modulated by, among other factors, the isotype of
the 9-cis retinoid X receptor (RXR) heterodimeric part-
ner [3]. Heterodimerization with RXRγ leads to binding
to a strong element, while heterodimerization with RXRα
favors binding to weak elements [3].
Ligand-bindingpropertiesofPPARs
Compounds that trigger the expression of a reporter
gene, when added to a cell culture medium, have been
identiﬁed as PPAR activators. Studies revealed that these
compounds selectively bind to various PPAR isotypes
(Figure 1 and Table 1). It has been demonstrated that the
prostaglandin 15-deoxy-∆12,14-prostaglandin J2 and the
antidiabetic thiazolidinediones are ligands for the PPARγ
[17, 18, 19]. Additionally, leukotriene B4 and several
known peroxisome proliferating agents including Wy-
14,643 and ﬁbrates bind speciﬁcally to PPAR α [20, 21].
Fatty acids and eicosanoids also bind to PPARα,w i t h
varying degrees of speciﬁcity [17, 22, 23]. A novel series
of ﬁbrates has recently been described as speciﬁc ligands
for the PPAR δ subtype [4].
BIOLOGICAL ROLES OF PEROXISOME
PROLIFERATOR-ACTIVATED RECEPTORS
Although the focus of this review is on the involve-
ment of PPARs in inﬂammatory diseases, it is important
that we present a brief overview of the plethora of other
functions controlled by these receptors. A PPAR subtype-
speciﬁc role has been discovered in several important hu-
man diseases and pathological conditions [2, 4, 10, 19].
These receptors have been implicated in aging [24, 25],
aging-related diseases [25, 26], inﬂammation and immu-
nity [2, 10, 27, 28, 29], as well as in obesity [30, 31, 32, 33]
and responsiveness to insulin [34]. Furthermore, PPARs
have been reported to play a signiﬁcant role in the regula-
tion of fertility [2, 10, 35], and in cancer [2, 10, 36, 37, 38,
39].
Aging
Senescence is associated with a decline in peroxisomal
enzymeactivities[24,25].Ourmostrecentresultssuggest
that peroxisomal decline, as a function of aging, may be
the result of a decline in the availability of the obligatory
PPARα heterodimer partner RXR α, and not PPAR α itself
in senescent animals [40]. The importance of this aging-
associated peroxisomal enzyme deﬁciency lies in the fact
that very-long-chain fatty acids are metabolized exclu-
sively in peroxisomes [41]. Thus, PPARs appear to play an
important role in maintaining membrane structure and
function by regulating fatty acid balance [42, 43, 44].
Obesityanddiabetes
There are three variants of PPAR γ; γ1, γ2, and γ3
[3]. Adipose expression of PPAR γ2 mRNA increases in
obese human subjects, with a strong positive correlation
between the ratio of PPAR γ2t oγ1 and the body mass
index [30]. Interestingly, diﬀerential expression of PPAR
γ in intra-abdominal and subcutaneous adipose tissues in
humans may underscore the association of visceral, but
not subcutaneous, fat with obesity [31].
The recognition that PPAR γ is the receptor for the
antidiabetic thiazolidinediones linked this receptor to
glucose homeostasis in rodents and humans [21, 34].
There appears to be an inverse relationship between the158 J. Youssef and M. Badr 2004:3 (2004)
level of PPAR γ mRNA and that of nonfunctional insulin
receptors in human visceral adipose tissue [31]. PPAR γ
ligands improve insulin sensitivity in vivo [32].
Cellcyclecontrolandcancer
A link between PPAR and cancer was ﬁrst drawn af-
ter it became clear that PPAR agonists cause a dramatic
increase in the incidence of liver tumors in mice and rats
[24, 45]. Cell proliferation and peroxisomal production
of H2O2 are two major factors enhanced by peroxisome
proliferators and are implicated in liver cancer caused by
thesechemicals[36,37].Alternatively,severalstudieshave
shown that agonists of PPARs suppress apoptosis in the
l i v e ri nap r o c e s sm e d i a t e db yP P A Rα [46, 47]. Apoptosis
appears to be a safeguard to prevent cells with DNA dam-
age from progressing to a tumor [38], where hepatocytes
resistanttoapoptoticdeathmayrepresentpreferentialtar-
gets for promotion by PPAR agonists.
The potential role of PPAR in cancer formation in hu-
mans is controversial [48]. While two recent studies im-
plicated PPAR γ in promotion and development of colon
cancer [31, 39], a third report indicated a possible pro-
t e c t i v er o l ef o rP P A Rγ agonists against colon cancer in
humans [37]. It is evident that mice genetically predis-
posed to develop polyps in the colon show an increased
number of polyps when subjected to PPAR γ agonists
orally [31, 39]. Conversely, it was demonstrated that hu-
man colon tumor cell lines both in culture and in nude
mice respond to PPAR γ agonists with a reduced rate of
growthandanincreaseddegreeofdiﬀerentiation[49].We
recently proposed that PPARγ agonists may be beneﬁcial
in combating breast cancer in humans [50]. Furthermore,
a recent report suggested that inhibiting PPAR δ may be
responsible for reducing the incidence of colorectal can-
cer caused by nonsteroidal anti-inﬂammatory drugs [51].
Conﬁrmation of the involvement of PPAR δ in colorec-
talcancerawaitsmoredeﬁnitivestudiesusingcompounds
speciﬁc to this PPAR subtype [4].
Fertility
PPAR δ was detected in the uterus during embryo im-
plantation in mice [35]. Similar to the expression pattern
oftheprostacyclinsynthaseenzyme,expressionofPPARδ
was also induced in the stroma surrounding the implant-
ing blastocyte and became localized in the decidual zone
after implantation [35]. Supporting evidence for a PPAR
δ-mediated role in fertility was obtained when activators
of this PPAR subtype restored implantation in COX2 null
mice [35]. This ﬁnding is in support of the hypothesis
stipulating that prostacyclin and/or its metabolite(s) reg-
ulate embryo implantation by activating PPAR δ [4, 46].
PPAR γ also appears to play an important role in embry-
onic development [10]. Mice deﬁcient in this PPAR sub-
type showed embryonic lethality, presumably a result of
a major default in placental development [10]. PPAR α,
however, does not appear to have a vital role in develop-
ment [10].
MODULATION OF INFLAMMATORY RESPONSES
BY AGONISTS OF PPARs
Inﬂammation
Inﬂammation is a series of characteristic tissue re-
sponses to injury or insult. Elevated tissue levels of tu-
mor necrosis factor alpha (TNFα), Interleukin-1 (IL-1),
and Interleukin-6 (IL-6), among other proinﬂammatory
mediators, have been observed in experimental animal
models of inﬂammation as well as in humans follow-
ing trauma, severe blood loss, or sepsis. Onset of release
of these mediators, and their tissue half-life vary signiﬁ-
cantly, based on the noxious stimuli to which tissue has
been exposed [14]. Because of the impact of inﬂamma-
tion, acute or chronic, on the quality of life, intense re-
search is directed toward the discovery of novel thera-
peutic agents to prevent/reverse these processes. Among
the most promising compounds currently pursued to-
ward achieving this goal are the PPAR agonists [4, 52].
RoleofPPARsininﬂammation
Both PPARα and PPARγ receptor subtypes have been
reported to regulate inﬂammatory responses, both in vivo
and in vitro [53, 54]. However, the extent of this regula-
tion, and indeed its direction, are controversial. No pub-
lished reports are readily available on the involvement of
PPARδ in inﬂammation control. Potential modulation of
inﬂammatory responses by PPARδ agonists has only been
recently investigated in our laboratories.
PPARα
The ﬁrst indication of a role by PPAR in modulat-
ing inﬂammation was evidenced by the demonstration
that Leukotriene B4 (LTB4), a potent chemotactic in-
ﬂammatory eicosanoid [55], binds to PPARα and in-
duces transcription of genes of the ω-a n dβ-oxidation
pathways that can catabolize LTB4 itself [20]. PPAR α
null mice showed a prolonged inﬂammatory response
when challenged with LTB4 or its precursor, arachidonic
acid, possibly due to the absence of stimulation of the
catabolic pathways, hence, the increased duration of the
inﬂammation [20]. Furthermore, dietary n-3 fatty acids
and cloﬁbrate, which also bind to PPARα,h a v eb e e n
reported to accelerate catabolism of LTB4 in granulo-
cytes and macrophages [56, 57]. It is postulated that
activation of PPARα by nonsteroidal anti-inﬂammatory
agents contributes to the anti-inﬂammatory, antipyretic,
and analgesic properties of these drugs through stimula-
tion of oxidative pathways involved in the catabolism of
eicosanoids [3]. Inhibition of the synthesis of proinﬂam-
matory molecules such as IL-6 and prostaglandins also
appears to participate in PPARα-mediated control of in-
ﬂammation, via a decreased activity of NF-κB[ 58]. Con-
versely, dietary treatment with PPARα agonists increased
lipopolysaccharide-induced plasma TNFα levels, an eﬀect2004:3 (2004) PPARs and Inﬂammation 159
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Figure 2. Site-speciﬁc inhibition of carrageenan-induced paw inﬂammation by PPAR agonists. The hatched bar indicates the site at
which PPAR agonists interfere with the inﬂammatory process.
thatwassigniﬁcantlydiminishedinPPARα-deﬁcientmice
[59].Theselatterresultssuggestaproinﬂammatoryroleof
PPARα.
The postulate that PPARα receptor activation en-
hances the degradation of lipid-derived proinﬂammatory
mediators, such as LTB4 [20], is not supported by re-
cent ﬁndings in our laboratories, using the carrageenan-
induced rat paw edema model of inﬂammation [60].
First, we observed that the PPARα agonist perﬂuorooc-
tanoic acid (PFOA) produced robust anti-edema eﬀects
when administered minutes before carrageenan [60], yet
denovo synthesisofenzymes requiresamuchlongertime
period, and is therefore expected to take hours follow-
ing the administration of PPAR agonists. Second, when
as u ﬃcient time for de novo enzyme synthesis was al-
lowed by administering PFOA 12 or 24hours before car-
rageenan, we did not observe an enhanced anti-edema
eﬀect compared to PFOA administered only 30minutes
before carrageenan [60]. Consequently, we speculate that
PFOA inhibits the levels of proinﬂammatory mediators
released during the induction of inﬂammation (Figures 2,
3,a n d4).
PPARγ
Recent studies demonstrate that in addition to PPAR
α,P P A Rγ may also play an important role in inﬂamma-
tion. However, the contribution of PPARγ to the inﬂam-
matoryresponseisalsounclear[53].Whileseveralstudies
showed that PPARγ activation blocked the production of
proinﬂammatory mediators [61, 62, 63, 64], other stud-
ies proposed that PPARγ has no anti-inﬂammatory ac-
tivity, or might indeed exert a pro-inﬂammatory response
[53, 65, 66].
Reductionofnitricoxide(NO)production
byPPARγ agonists
NO acts not only as a signal molecule mediating vari-
ous physiological functions, but it also plays an important
role in inﬂammatory processes [67, 68]. Injection of LPS
and IFN-γ into rat cerebellum induced the expression of
iNOS, which produces NO, in cerebellar granule cells and
caused subsequent cell death [69]. In this model, PPARγ
agonists reduced iNOS expression and cell death, whereas
a selective COX-2 inhibitor had no eﬀect [69]. Further-
Cytokines
Inﬂammation
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PPAR
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Immune cell
Inﬂammatory insult
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species
Figure 3. A scheme depicting potential mechanisms via which
anti-inﬂammatory eﬀects are exerted by PPAR agonists. Solid
lines represent potential PPAR-mediated eﬀects. Dashed lines
represent proposed mechanisms by which PPAR agonists may
act via PPAR-independent mechanisms to diminish inﬂamma-
tion.
more, mesangial cell production of NO was inhibited by
PPARγ agonists [70]. These ﬁndings suggest that PPARγ
regulates the activity of iNOS and activation of this PPAR160 J. Youssef and M. Badr 2004:3 (2004)
subtype controls inﬂammation by diminishing NO pro-
duction.
RegulationofcytokineproductionbyPPARγ
Cytokines produced by activated macrophages/foam
cells, including the macrophage-colony stimulating fac-
tor, IL-1, and TNFα, form the basis of the inﬂamma-
tory component of the atherosclerotic lesions and pro-
mote proliferation of smooth muscle cells [3]. Necro-
sis of macrophages and lipid-loaded foam cells releases
their intracellular contents, resulting in an accumula-
tion of extracellular components that form the ﬁbrous
cap of the atheromatous lesion [57]. Eventually, the rup-
ture of this plaque leads to the acute arterial obstruction
[3]. Many aspects of these pathological processes might
be modulated by PPAR γ which is upregulated by ox-
idized LDL [27, 65]. Furthermore, expression of PPAR
γ has indeed been demonstrated in mouse and human
atherosclerotic lesions [27, 28]. In contrast to this appar-
ently proatherosclerotic action of PPAR γ ligands, these
agonists have been reported to prevent atherosclerotic
plaqueprogression[28].Furtherstudiesareneededtode-
termine the exact role of PPAR γ in the development of
atherosclerosis.
Our studies revealed a positive relationship between
anti-edema activity of PPARγ agonists in vivo [60]a n d
their ability to activate PPARγ in vitro [4]. Thus, the high
aﬃnityPPARγ agonistrosiglitazone,butnotthelowaﬃn-
ity agonist troglitazone, signiﬁcantly inhibited paw edema
[60]. This suggests that, like the PPARα receptor, activa-
tion of the PPARγ receptor leads to anti-inﬂammatory ef-
fects in vivo. Also, as with the PPARα agonists, rosiglita-
zone was eﬀective only when given prior to, but not af-
ter, carrageenan. Therefore, PPARγ also appears to reg-
ulate the induction phase of inﬂammation (Figures 2, 3,
and 4).
RoleofPPARγ inneurodegenerative
andautoimmunediseases
Release of inﬂammatory mediators has been postu-
lated to play a major role in the etiology of a variety
of aging-related neuronal degenerative diseases, such as
Alzheimer’s disease (AD) [71]. The role of microglial-
mediated inﬂammatory mechanisms in the etiology of
AD has achieved prominence owing to recent compelling
epidemiological and investigative ﬁndings [71]. Epidemi-
ological studies have shown a reduced risk of AD among
long-term users of nonsteroidal anti-inﬂammatory drugs
(NSAIDs). The formation of amyloid plaques in AD is ac-
companied by the recruitment of microglia to these de-
posits [71]. The interaction of these cells with amyloid
ﬁbrils leads to their phenotypic conversion into a reactive
phenotype [71]. The activation of microglia results in the
elaboration of a diverse array of pro-inﬂammatory secre-
tory products including cytokines, chemokines, reactive
oxygen species, and nitrogen species, as well as of other
acute phase proteins [71].
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Figure 4. Eﬀect of various PPAR agonists on the temporal
proﬁle of paw edema. Rats were treated intraperitoneally with
(100mg/kg) of the PPARα agonist PFOA (a), the PPARγ ag-
onist rosiglitazone (b), or the PPARδ agonist L783484 (c) 30
minutes before induction of inﬂammation. As indicated by the
arrow, carrageenan (1%, intraplantar) was injected at t = 0.
Carrageenan-induced edema is reﬂected by an increase in paw
thickness. Values represent mean ± SEM, n = 5–8 rats per
group; ∗P<. 05.2004:3 (2004) PPARs and Inﬂammation 161
Previously, the anti-inﬂammatory actions of NSAIDs
and their therapeutic beneﬁt in treating AD were at-
tributed to the ability of these drugs to inhibit the cy-
clooxygenases and PGE2 production [72]. Based on the
ﬁndings showing that PPARγ ligands prevented the in-
crease in Aβ-stimulated COX-2 expression in microglia
and monocytes [71], it was determined that the neuro-
protective eﬀect of NSAIDs and PPARγ ligands was not
attributabletoareductionincyclooxygenaseactivity[71].
This conclusion is supported by the fact that the COX-
2-speciﬁc inhibitorNS-398 failed to promote neuron sur-
vival [71]. Furthermore, extended use of aspirin, a potent
COX inhibitor, is not associated with a reduction in the
risk of AD [72]. Consequently, it was concluded that mi-
croglial COX-2 activity and prostaglandin production are
not necessary components in the neuronal death process
[71], and that the beneﬁcial eﬀects of NSAIDs in AD are
attributable principally to the actions of these drugs as
PPAR agonists, rather than via their ability to inhibit cy-
clooxygenase activity [71].
Several studies have also investigated the role of
PPARγ ligands in modifying animal models of autoim-
mune diseases. In a mouse model of inﬂammatory bowel
disease, thiazolidinediones markedly reduced colonic in-
ﬂammation [73]. It was consequently proposed that this
eﬀect might be a result of a direct eﬀect on colonic ep-
ithelial cells, which express high levels of PPARγ and
can produce inﬂammatory cytokines [73]. PPARγ lig-
ands, 15d-PGJ2 and troglitazone, ameliorated adjuvant-
induced arthritis with suppression of pannus formation
and monouclear cell inﬁltration in rats [74].Niino et al
[75] examined the eﬀect of a thiazolidinedione on exper-
imental allergic encephalomyelitis and found that these
PPARγ agonists attenuated inﬂammation and decreased
clinical symptoms in this mouse model of multiple scle-
rosis.
PPARδ
No published reports are available on the impact of
PPARδ agonists on inﬂammation. This may, in part, be
due to the fact that PPARδ-speciﬁc ligands are not read-
ily, commercially available. Preliminary data from our
laboratory show that L783483 diminished carrageenan-
inducedpawedemainrats(Figure 4).Althoughthiscom-
pound has PPARγ activity in addition to being a PPARδ
agonist [13], the fact that it showed 2-fold eﬃcacy in re-
ducingpawedemacomparedtothepotentPPARγ agonist
rosiglitazone(Figure 4)suggeststhatPPARδ mayalsoplay
a role in controlling inﬂammatory responses. It remains
to be investigated, however, whether L783483 modulates
paw edema if administered after the induction of inﬂam-
mation by carrageenan, as was the case with agonists of
both PPARα and PPARγ (Figure 2).
The development of edema in the rat paw following
the intraplantar injection of carrageenan has been de-
scribedasabiphasicevent(seeTable 2)[14,15,16,76].In
response to carrageenan-induced paw edema, it has been
Table 2. Carrageenan-evoked proinﬂammatory mediators.
Mediator Reference(s)
PGE2 [14]
Nitric Oxide [15]
Superoxide anion [15]
Peroxynitrite [15, 16]
documented that while cNOS appears to be involved in
the early phase of inﬂammation, iNOS participates in the
sustained phase [15, 16]. Early in the inﬂammatory re-
sponse to carrageenan, while inﬁlterating neutrophils are
not the source of iNOS-derived NO [15, 16], these cells
appear to contributeO
−
2 to the early phase of inﬂamma-
tion [15, 16]. Therefore, our ﬁndings [60] suggest that
anti-inﬂammatory eﬀects of PPAR agonist are likely due
to the ability of these chemicals to interfere with cNOS,
but not with iNOS. Given the above studies, the rele-
vance of PPARs and the utility of treatment with PPAR
agonists in diseases with inﬂammatory or autoimmune
pathogenesis will likely continue to remain a research
focus.
PPAR-independentanti-inﬂammatory
effectsofPPARagonists
Several recent studies report that agonists of both
PPARα and PPARγ produce eﬀects that are not me-
diated by PPARs. However, the nature of these PPAR-
independent mechanisms is not understood at this time.
PPARαagonists
I nam o s tr e c e n tr e p o r t[ 77], treatment of spleno-
cytes with the PPARα agonist Wy-14,643 as well as by
other ﬁbrates led to marked increases in Interleukin-
4 (IL-4) release. Surprisingly, however, Wy-14,643 also
induced IL-4 expression in splenocytes from PPARα
knockout mice [77]. Furthermore, GW 7,647, a potent
and speciﬁc PPARα ligand, did not augment IL-4 un-
der conditions used with Wy-14,643 [77]. These ﬁndings
suggest that modulating inﬂammatory responses exerted
by Wy-14,643 and by other ﬁbrates in lymphocytes may
not be mediated exclusively through PPARα-dependent
mechanisms [77].
PPARγ agonists
Numerous studies present evidence for receptor-
independent anti-inﬂammatory eﬀects caused by PPARγ
agonists [69, 70, 73, 75]. A study showed that the PPARγ
agonist troglitazone enhanced IL-1-induced nitric ox-
ide synthase (NOS) mRNA levels in vascular smooth
muscle cells despite the absence of detectable PPARγ
levels in these cells [64]. However, these eﬀects were
in contrast to those obtained in response to 15-deoxy-
∆12,14 prostaglandin J2, the natural ligand for PPARγ162 J. Youssef and M. Badr 2004:3 (2004)
[78]. Another study [79] reports that both 15-deoxy-
∆12,14 prostaglandin J2 and the thiazolidinedione drugs
have anti-inﬂammatory eﬀects that are independent of
PPARγ. Furthermore, in activated microglia, while 15-
deoxy-∆12,14 prostaglandin J2 suppressed iNOS promotor
activityanddecreaseditsmRNAandproteinlevels,trogli-
tazone, a speciﬁc PPARγ ligand, failed to produce similar
eﬀects [80]. These ﬁndings further support the conclu-
sion that anti-inﬂammatory action exerted by 15-deoxy-
∆12,14 prostaglandinJ2 mayinvolvesitesotherthanPPARγ
[80]. Indeed, it has been shown that the two structurally
similar thiazolidinediones troglitazone and rosiglitazone
cause diﬀerent conformational changes in the PPARγ,
upon binding to this receptor [81]. Further, troglitazone
may behave as a partial agonist under certain physiologi-
cal circumstances, and as a full agonist under others [81].
The exact mechanisms involved in these non-
PPAR-mediated eﬀects of PPAR agonists are not well
understood. However, it is possible that these agonists
act via receptors other than PPARs to aﬀect changes in
the synthesis and/or release of pro-inﬂammatory medi-
ators (Figure 3). Alternatively, PPAR agonists may act via
a nonreceptor-mediated mechanism such as antioxidants
or free-radical scavengers (Figure 3). The latter potential
is supported by experimental ﬁndings showing that ad-
ministering exogenous antioxidants, for example, vitamin
E-likecompounds,orelementsoftheendogenouscellular
antioxidant defensemechanisms,forexample,superoxide
dismutase, exhibited protective eﬀects against inﬂamma-
tory insults [82].
SUMMARY AND CONCLUSIONS
Demonstrating that PPAR agonists diminished in-
ﬂammatory responses in several experimental models of
inﬂammation has led to a surge in interest in these ag-
onists as potential therapeutic agents to treat inﬂamma-
tory diseases. Although various postulates have been ad-
vanced in an attempt to explain the mode of action of
these compounds as anti-inﬂammatory agents, the exact
mechanism by which they act remains elusive. Our recent
resultsstronglysuggestthatagonistsofPPARαandPPARγ
interfere with the early phase of inﬂammation, without
inﬂuencing its late phase. An unpublished ﬁnding from
our laboratories shows that activation of PPARδ also elic-
its an anti-inﬂammatory response. It is not yet clear, how-
ever, whether these three PPAR receptor subtypes share a
common mechanism or act independently to control in-
ﬂammatory processes.
FUTURE DIRECTIONS
The PPAR-independent anti-inﬂammatory eﬀects of
PPAR agonists warrant investigation to localize potential
non-PPAR site(s) of action of these compounds. A vast
amount of circumstantial evidence implicates oxygen-
derived free radicals (especially superoxide and hydroxyl
radical) and high-energy oxidants (such as peroxynitrite)
as mediators of inﬂammation [16]. Production of reac-
tive oxygen species (ROS) such as O
−
2 ,H 2O2,a n dH O .
occurs at the site of inﬂammation and contributes to tis-
sue damage [16]. Interventions which reduce the gener-
ation, and/or the eﬀects of ROS exert beneﬁcial eﬀects
in a variety of models of inﬂammation [83]. Since su-
peroxide dismutase (SOD), but not catalase, the iron-
chelator desferrioxamine or serine protease inhibitor, has
been shown to attenuate neutrophil-mediated cell in-
jury [84], it is strongly suggested that O
−
2 plays a ma-
jor role in neutrophil-induced inﬂammation. Interest-
ingly, SOD mimetics are superior to SOD in attenuat-
ing neutrophil-mediated cell injury [84, 85], possibly be-
cause of their superior intracellular accessibility and also
due to the fact that these compounds, in contrast to
SOD, do not react with H2O2, a reaction which is known
to result in the formation of HO. via Fenton chemistry
[85].
In addition to ROS, it has also been reported that NO.
playsaroleinthepathophysiologyassociatedwithvarious
models of inﬂammation [15, 86, 87]. In addition to NO.,
ONOO− is also generated during inﬂammation [15]. In
arthritis, nitrotyrosine levels increase in plasma and syn-
ovial ﬂuid [88]. In ileitis [89] and in endotoxin-induced
intestinal inﬂammation, there is immunocytochemical
documentation of augmented ONOO− production [90].
The pathophysiological role of NO. and ONOO− in the
gastrointestinal damage elicited by endotoxin or chronic
inﬂammation has been the subject of a variety of detailed
investigations [91]. The ability of ONOO− to cause severe
colonic inﬂammation has been documented [91], and the
production of ONOO− in colitis may be even more pro-
nounced because of the parallel down-regulation of SOD
[92], which makes the O
−
2 available for coupling with
NO. [92]. It is reported that PPAR agonists decrease NOS
activity and the production of NO in experimental in-
ﬂammation models [29, 62]. However, the question of
whether agonists of PPARs act as SOD mimetics, or via
other mechanisms, to neutralize ROS deserves an answer
and it is currently being planned to investigate this excit-
ing potential.
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